Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage

Frank Karkossa1, Antonia Krueger1, Jana Urbaniak1

  • 1Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, Ernst Moritz Arndt University Greifswald, 3 Felix Hausdorff Street, 17489, Greifswald, Germany.

AAPS Pharmscitech
|December 3, 2016
PubMed

Insights

Developing a novel in vitro dissolution model for pediatric drug release can reduce the need for in vivo studies in children. This biorelevant setup accurately simulates infant gastrointestinal conditions, aiding pediatric dosage form development.

Area of Science:

  • Pharmacokinetics and Drug Delivery
  • Pediatric Pharmacology
  • In Vitro Testing Methodologies

Background:

  • Reducing in vivo studies in children is crucial for ethical and practical reasons.
  • Existing in vitro dissolution models do not adequately represent pediatric gastrointestinal physiology or dosing.
  • Pediatric drug development requires specialized methods to ensure safety and efficacy.

Purpose of the Study:

  • To design and validate a novel in vitro dissolution model for simulating pediatric gastrointestinal conditions.
  • To enable biorelevant testing of drug release from pediatric dosage forms.
  • To support the development of pediatric formulations and reduce in vivo testing.

Main Methods:

  • Development of a miniaturized dissolution system with small fluid volumes.
  • Utilization of physiological bicarbonate-based test media.
  • Implementation of precise pH control using a pHysio-stat® device.
  • Screening in vitro drug release of a valproate-extended release formulation.

Main Results:

  • The novel dissolution setup successfully simulated pediatric gastrointestinal conditions.
  • In vitro drug release profiles for the valproate formulation showed controlled release over 12 hours.
  • Results aligned with product information and existing in vivo food effect study data.

Conclusions:

  • The new dissolution setup is a promising in vitro screening tool for pediatric dosage forms.
  • This method can potentially reduce the number of pharmacokinetic studies required in children.
  • Biorelevant in vitro testing is valuable for pediatric drug development.

Related Concept Videos

In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
416
In Vitro Drug Dissolution: Compendial Testing Models II01:09

In Vitro Drug Dissolution: Compendial Testing Models II

Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
448
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
345
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
369
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605